Promoter holding
64.27%
IM
Integris Medtech Limited - Due diligence report
A 360° intelligence report on Integris Health: trust score, financial health, credit view, compliance, directors, growth and distress signal…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Integris Health — 360° Intelligence Report
Generated from MCA filings & public records76/100
Trust Score
Low Risk
Integris Health is assessed as Low Risk with a Trust Score of 76/100. Integris Health is an active public limited indian non-government company incorporated in 2008, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.
Report generated on 28 Jun 2026 from the latest processed filings. Integris Medtech Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
76/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
81/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
75/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
Charges position: 7 open (268.00 cr) · 2 satisfied (4.00 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Hdfc Bank Limited | 5 | 48.0 cr |
| Citi Bank N.A. | 1 | 48.0 cr |
| Kotak Mahindra Bank Limited | 1 | 48.0 cr |
| Others | 1 | 48.0 cr |
| Bank Of Baroda | 1 | 48.0 cr |
Compliance Score: 81/100 Low Risk
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 1 court forum(s).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 75/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ARJUN OBEROI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJANI KESARI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HEMANT SULTANIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| GURMIT SINGH CHUGH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Darpan Batra | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANNASWAMY VAIDHEESH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAMESH SUBRAHMANIAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AVNISH MEHRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PUNITA SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VISHAL OMPRAKASH GOENKA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PROBIR DAS | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Probir Das | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 12 directors on the board.
- No disqualified or deactivated DINs.
- 11 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Evercure Holding Pte Ltd
Subsidiaries
2
Group entities
2
Capital events
4 allotment(s) · 2 transfer(s)
Promoters hold the largest single block of equity - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Artic Holding Gmbh | Subsidiary Company | 74.00% |
| Transhealth Private Limited | Subsidiary Company | 74.00% |
| Translumina Gmbh | Subsidiary Company | 74.00% |
| Translumina Therapeutics Llp | Subsidiary Company | 74.00% |
| Transvalve Health Private Limited | Subsidiary Company | 74.00% |
| Evercure Holding Pte Ltd | Holding Company | 74.00% |
Key managerial personnel: HEMANT SULTANIA (CFO) · PROBIR DAS (CEO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 55
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Asset base grew 24% - capacity expansion.
Operating for 18+ years.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Outside liabilities up 0.86 in a year.
9 director exits within 2 years.
7 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence72/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 3 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment66/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 7 open charge(s) of 268.00 cr already registered.
- Compliance record supports lending.
Investor view74/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events13 Oct 2025
Charge created
Hdfc Bank Limited - 60.00 cr
07 Oct 2025
Director ceased
GURMIT SINGH CHUGH
Director ceased
PUNITA SHARMA
01 Oct 2025
Charge created
Hdfc Bank Limited - 17.00 cr
26 Sep 2025
Director appointed
Darpan Batra (Company Secretary)
21 Sep 2025
Director ceased
AVNISH MEHRA
30 Aug 2025
Director appointed
Probir Das (Ceo)
26 Aug 2025
Director appointed
ANNASWAMY VAIDHEESH (Director)
25 Aug 2025
Director appointed
HEMANT SULTANIA (CFO)
Director appointed
PROBIR DAS (CEO)
Director ceased
KEWAL KRISHAN
07 Aug 2025
Director ceased
PROBIR DAS
01 Aug 2025
Director appointed
RAJANI KESARI (Director)
Director appointed
RAMESH SUBRAHMANIAN (Director)
21 Jul 2025
Director appointed
ARJUN OBEROI (Nominee Director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
12 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 2 subsidiary(ies) - assess on a consolidated basis.
Promoters hold the largest single block of equity as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 4 security allotment(s) - amounts available in the full report.
12 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Balkishan Dass Subhash Chand Ispat Private Limited | U28999DL2011PTC215598 | Delhi, Delhi, India |
| Amvigor | U24233MH2013PTC245776 | Mumbai, Maharashtra, India |
| Avaids Technovators Private Limited | U74899DL1988PTC031707 | New Delhi, Delhi, India |
| Ceid Consultants And Engineering Private Limited | U35200PB2012PTC036910 | Abohar, Punjab, India |
| Care Formulation Labs Private Limited | U24100DL2010PTC210765 | New Delhi, Delhi, India |
| Yeoman Marine | U35999MH2015PTC268155 | Mumbai, Maharashtra, India |
| The Malt Company | U15533DL1970PTC005229 | New Delhi, Delhi, India |
| Secure Infratech Finserv And Securities Limited | U74999WB2012PLC183377 | Kolkata, West Bengal, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Integris Health before audits and certifications: compliance score 81/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Integris Health: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Integris Health - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 76/100, distress signals and MSME payment-delay disclosures - know whether Integris Health pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Integris Health - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Integris Health an active company?
Integris Health has MCA status “Active” with a compliance score of 81/100 (Low Risk).
Is Integris Health financially healthy?
Integris Health has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.
Should I do business with Integris Health?
Its overall Trust Score is 76/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Integris Health?
The ultimate holding entity is Evercure Holding Pte Ltd. 12 active director(s) are on record.
Does Integris Health have loans or charges against its assets?
7 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.
Is Integris Health up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 81/100 (Low Risk).
Is it risky to lend to Integris Health?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
